日本語フィールド
著者:荒金 尚子題名:総説 肺癌におけるliquid biopsyの意義発表情報:肺癌 巻: 60 号: 2 ページ: 67 - 73キーワード:概要:ctDNA(circulating tumor DNA)を用いたliquid biopsyは,非侵襲性でありリアルタイムの,かつ個体全体の遺伝子異常を反映する新規の臨床検査として広まってきた.従来はPCRを基礎とした単一遺伝子変異が主であったが,最近では次世代シークエンスを用いた網羅的遺伝子解析のデータが発表され,より精確な分子標的薬効果予測が可能になりつつある.一方で,liquid biopsyの限界として,腫瘍量が少ない場合,胸郭内,中枢神経系に限局している症例ではctDNA陽性率が低いことが挙げられる.さらに,空間的診断能がないため腫瘍進展時に増大する腫瘍不均一性により,検査結果が治療効果と結びつかない場合もある.以上のliquid biopsyの特徴を理解し,この検査系を有効利用することが重要である.抄録:英語フィールド
Author:Aragane NaokoTitle:Invited Review Articles Significance of a Liquid Biopsy on Lung CancerAnnouncement information:Haigan Vol: 60 Issue: 2 Page: 67 - 73An abstract:A liquid biopsy using circulating tumor DNA (ctDNA) has gained acceptance as a new, non-invasive clinical examination that reflects genomic alterations in the whole body in real time. It mainly involves a polymerase chain reaction-based single gene mutation test, but the results of comprehensive genomic analyses using next-generation sequencing have been recently reported, suggesting the possibility of the more precise prediction of molecular target therapy efficacy. However, there are some limitations associated with a liquid biopsy, including the low detection rate of ctDNA in cases with a low tumor burden or lesions limited to the intra-thoracic or central nervous system. In addition, it does not have any special diagnostic ability, and the origin of the genomic alterations detected with ctDNA is unclear. Therefore, the detection of ctDNA does not always reflect treatment efficacy, due to tumor heterogeneity. It is important to understand these characteristics of a liquid biopsy and use it effectively.